Propanc Biopharma, Inc. has received a granted US patent from the United States Patent and Trademark Office (USPTO) covering composition of matter claims involving trypsinogen and chymotrypsinogen. The additional composition claims are a continuation from the original foundation patent in the U.S., and as a result, both method of treatment and composition claims now protects the Company’s lead product candidate, PRP, a pharmaceutical composition consisting of two proenzymes, trypinsogen and chymotrypsinogen, for treating cancer.

The granted patent issued by the USPTO now confers exclusive rights to the Company’s lead product, PRP, by demonstrating that compositions comprising trypsinogen and chymotrypsinogen exhibit a synergistic ability to inhibit the growth of various cancer cell lines.

"We continue to grow and strengthen our intellectual property portfolio and it is pleasing to receive additional patent claims for PRP in one of our most important global jurisdictions," said James Nathanielsz, Propanc’s Chief Executive Officer. "Presently, we have 65 patents either in force, or pending, in major global regions around the world, and this is very significant as we advance PRP towards human trials."

"We continue to fund research programs with our university partners, and plan to file additional patent applications in the future," said Dr Julian Kenyon, Propanc’s Chief Scientific Officer. "Intellectual property lies at the heart of any early stage Biotech company and we look forward to expanding our portfolio covering further aspects of our invention related to PRP, especially as we advance further down the clinical development pathway."

-----------------------------------------------------------------------
Editor's Note:

For any copyright disputes involving the content, 

please email: Julia.Zhang@ubmsinoexpo.com to delete.